Search
alkylating agent
Adverse effects:
1) increased incidence of acute myelocytic leukemia (AML)
a) often preceded by myelodysplastic syndrome
b) peak incidence 4-6 years after alkylating agent therapy
2) non-random cytogenetic abnormalities
a) chromosome 7 deletions
b) trisomy 8
Interactions
drug adverse effects of alkylating agents
Related
alkylating agent combination
Specific
alkylating agent nitrogen mustard
alkylating agent nitrosourea
alkylating agent triazene
altretamine (Hexalen)
bendamustine (Treanda, Cytostasan, Ribomustin)
busulfan (Myleran)
diazomethane; azimethylene
lurbinectedin (Zepzelca)
phenoxybenzamine (Dibenzyline)
procarbazine (Matulane, Natulan, ibenzmethyzin)
thiotepa; thiophosphamide (Tespa, Thioplex)
General
antineoplastic agent (chemotherapeutic agent)
References
Medical Knowledge Self Assessment Program (MKSAP) 11, American
College of Physicians, Philadelphia 1998